Search by Drug Name or NDC

NDC 00173-0665-18 MEPRON 750 mg/5mL Details

MEPRON 750 mg/5mL

MEPRON is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is ATOVAQUONE.

MedlinePlus Drug Summary

Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia.

Related Packages: 00173-0665-18
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Atovaquone

Product Information

NDC	00173-0665
Product ID	0173-0665_a88a003d-2672-4782-8d24-62b2bf6e64ba
Associated GPIs	16400020001820
GCN Sequence Number	023399
GCN Sequence Number Description	atovaquone ORAL SUSP 750 MG/5ML ORAL
HIC3	W4K
HIC3 Description	ANTIPROTOZOAL DRUGS,MISCELLANEOUS
GCN	34490
HICL Sequence Number	006619
HICL Sequence Number Description	ATOVAQUONE
Brand/Generic	Brand
Proprietary Name	MEPRON
Proprietary Name Suffix	n/a
Non-Proprietary Name	atovaquone
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SUSPENSION
Route	ORAL
Active Ingredient Strength	750
Active Ingredient Units	mg/5mL
Substance Name	ATOVAQUONE
Labeler Name	GlaxoSmithKline LLC
Pharmaceutical Class	Antimalarial [EPC], Antiprotozoal [EPC]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA020500
Listing Certified Through	2024-12-31

Package

NDC 00173-0665-18 (00173066518)

Pricing Information	N/A
NDC Package Code	0173-0665-18
Billing NDC	00173066518
Package	210 mL in 1 BOTTLE (0173-0665-18)
Marketing Start Date	1995-02-28
NDC Exclude Flag	N